Accuracy of Pulse Oximeters With Profound Hypoxia

Sponsor
Respiree Pte Ltd (Industry)
Overall Status
Completed
CT.gov ID
NCT05139693
Collaborator
(none)
12
1
1
365.3

Study Details

Study Description

Brief Summary

The aim of this project is to test the accuracy of pulse oximeters during mild, moderate and severe hypoxia. This is done by comparing the reading of the pulse oximeter during brief, steady state hypoxia with a gold-standard measurement of blood oxyhemoglobin saturation (arterial blood sample processed in a laboratory hemoximeter). The data obtained is submitted by pulse oximeter manufacturers to the FDA for device approval.

Condition or Disease Intervention/Treatment Phase
  • Device: Respiree

Detailed Description

The study will include at least 10 subjects (up to 14 if needed to reach the 200 necessary data points to meet the ISO 80601-2-61:2017).

Per FDA guidance, at least 2, or 15% of the subjects will have dark skin.

Study Design

Study Type:
Observational
Actual Enrollment :
12 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Accuracy of Pulse Oximeters With Profound Hypoxia
Actual Study Start Date :
Dec 15, 2021
Actual Primary Completion Date :
Dec 16, 2021
Actual Study Completion Date :
Dec 16, 2021

Outcome Measures

Primary Outcome Measures

  1. To obtain a reading from the Respiree device that corresponds to the associated blood sample or a reference oximeter. [1 hour per subject]

    The number of subjects and the number of comparisons (paired pulse oximeter readings and arterial saturation values) is determined by current FDA guidance requirements. This is a minimum of 200 data points and 10 subjects. In the course of this type of study, some subjects may drop out, some readings can be lost due to motion or other interference and occasionally some do not consent.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 49 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. The subject is male or female, aged ≥18 and <50.

  2. The subject is in good general health with no evidence of any medical problems.

  3. The subject is fluent in both written and spoken English.

  4. The subject has provided informed consent and is willing to comply with the study procedures.

Exclusion Criteria:
  1. The subject is obese (BMI>30).

  2. The subject has a known history of heart disease, lung disease, kidney or liver disease.

  3. Diagnosis of asthma, sleep apnea, or use of CPAP.

  4. Subject has diabetes.

  5. Subject has a clotting disorder.

  6. The subject a hemoglobinopathy or history of anemia, per subject report or the first blood sample, that in the opinion of the investigator, would make them unsuitable for study participation.

  7. The subject has any other serious systemic illness.

  8. The subject is a current smoker.

  9. Any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigators' would interfere with the sensors working correctly.

  10. The subject has a history of fainting or vasovagal response.

  11. The subject has a history of sensitivity to local anesthesia.

  12. The subject has a diagnosis of Raynaud's disease.

  13. The subject has unacceptable collateral circulation based on exam by the investigator (Allen's test).

  14. The subject is pregnant, lactating or trying to get pregnant.

  15. The subject is unable or unwilling to provide informed consent, or is unable or unwilling to comply with study procedures.

  16. The subject has any other condition, which in the opinion of the investigators' would make them unsuitable for the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hypoxia Research Laboratory San Francisco California United States 94143

Sponsors and Collaborators

  • Respiree Pte Ltd

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Respiree Pte Ltd
ClinicalTrials.gov Identifier:
NCT05139693
Other Study ID Numbers:
  • 10-00437
First Posted:
Dec 1, 2021
Last Update Posted:
Apr 29, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 29, 2022